TrivarX Taps Radiopharmaceutical Veteran to Lead Brain Cancer Imaging Into Clinic
TrivarX appoints radiopharmaceutical veteran to lead Stabl-Im into clinic
TrivarX has appointed Dr Danielle Meyrick as Chief Executive Officer, effective 1 June 2026, positioning the company for clinical-stage execution as its Stabl-Im brain cancer imaging platform advances toward first-in-human studies. Dr Meyrick brings over 20 years of international experience spanning radiopharmaceuticals, isotope-based technologies, and clinical development from preclinical through to global Phase III trials and commercialisation.
The appointment addresses a critical inflection point for the ASX: TRI listed company as it transitions from technology development to clinical validation. Dr Meyrick’s expertise in radiopharmaceutical development directly aligns with the technical requirements of Stabl-Im, which uses stable isotope labelling combined with standard MRI to image cellular proliferation in brain tumours.
Her career includes senior leadership roles at ITM Isotopes Technologies Munich as Chief Medical Officer, Telix Pharmaceuticals (ASX: TLX) as Chief Medical Officer (APAC) and Global Head of Clinical Science, and GenesisCare as Chief Scientific Officer. At Telix, Dr Meyrick led clinical development strategy and regulatory engagement across radiopharmaceutical programs, providing direct experience relevant to advancing imaging-based diagnostic platforms through FDA, EMA, and TGA pathways.
The appointment follows TrivarX’s announcement that it is in advanced negotiations with leading Contract Research Organisations to support trial design and site activation for its Phase 1 safety study, targeted for completion this calendar year.
When big ASX news breaks, our subscribers know first
What is the Stabl-Im platform and why does it matter?
Stabl-Im combines stable isotope labelling with standard MRI scanning to visualise cellular proliferation within the brain non-invasively. Unlike radioactive isotopes used in PET scans, stable isotopes do not emit radiation, offering a potential safety advantage for repeated imaging in patients requiring long-term disease monitoring.
The technology targets replicating cells within brain tumours, enabling clinicians to detect disease activity and track progression using imaging equipment already installed at most radiology centres. Current imaging options for brain cancer patients rely heavily on contrast-enhanced MRI (which cannot distinguish active tumour from treatment effects) or PET/CT scans (which involve repeated radiation exposure and require specialised nuclear medicine facilities).
If validated in clinical trials, Stabl-Im could address an unmet need in neuro-oncology by enabling earlier detection of disease progression, more accurate monitoring of treatment response, and informed clinical decision-making without cumulative radiation burden. The platform approach also suggests potential applications beyond brain tumours, a strategic expansion flagged in management’s performance milestone structure.
Phase 1 trial preparations advance with CRO negotiations underway
TrivarX is in advanced negotiations with Contract Research Organisations to support its first-in-human clinical studies of Stabl-Im. Clinical trials are scheduled to commence shortly, with the Phase 1 safety study targeted for completion by the end of calendar year 2026.
The company continues to collaborate with Stabl-Im inventor and founder Dr Daniel Tillett on trial design, ensuring the study protocol reflects the platform’s technical requirements and regulatory pathway. Management has confirmed the company remains well funded to complete the proposed Phase 1 study without requiring additional capital.
According to the CEO’s performance targets disclosed in the employment agreement, the Phase 1 trial will enrol at least 20 subjects and is designed to establish safety and preliminary efficacy data for Stabl-Im as a brain tumour imaging agent. This study represents a critical validation milestone for the technology and provides a near-term clinical catalyst for investors.
CEO remuneration structure ties rewards to clinical milestones
Dr Meyrick’s compensation package links financial rewards directly to clinical and regulatory advancement, providing shareholders with transparency on management’s development timeline expectations. The structure includes a base salary of $300,000 per annum (exclusive of superannuation) and milestone-based incentives spanning short-term operational targets and long-term clinical development objectives.
For the FY26/27 period, Dr Meyrick is entitled to earn up to 50% of base salary as a short-term incentive, awarded 40% in cash and 60% in shares. This equity component aligns executive interests with shareholder value creation. The STI targets establish a clear operational roadmap for the company’s near-term execution priorities.
| Incentive Type | Milestone | Weighting/Quantity |
|---|---|---|
| STI FY26/27 | Phase 1 safety study completion (≥20 subjects) | 50% |
| STI FY26/27 | Pre-IND package submission to FDA | 25% |
| STI FY26/27 | In vivo animal efficacy studies beyond imaging | 25% |
| Options | 12 months service | 5M at $0.05 + 10M at $0.10 |
| Performance Rights | FDA IND allowance (brain tumour imaging) | 5M (2-year vest) |
| Performance Rights | Phase 2 imaging study ≥50 subjects | 5M (3.5-year vest) |
| Performance Rights | FDA IND beyond brain tumour imaging | 5M (3-year vest) |
| Performance Rights | Phase 1 ≥30 subjects beyond imaging OR FDA Fast Track/Breakthrough/Orphan | 10M (5-year vest) |
The long-term incentive structure extends across a 5-year development timeline and includes critical regulatory milestones that signal the company’s intent to pursue a US market pathway. FDA engagement targets (pre-IND package preparation, IND allowance) demonstrate management’s focus on establishing a clear regulatory route for commercialisation.
Performance rights tied to FDA designation (Fast Track, Breakthrough Therapy, or Orphan Drug status) and platform expansion beyond brain tumour imaging reflect the company’s strategic ambitions to broaden Stabl-Im’s clinical applications. The weighting of these milestones provides insight into management’s prioritisation of regulatory advancement and clinical validation.
Management confidence in near-term execution
Dr Meyrick’s public statements upon appointment emphasise the company’s current development stage and near-term clinical objectives:
Dr Danielle Meyrick, Incoming CEO
“I’m excited to be joining TrivarX at such a pivotal stage in the development of the Stabl-Im platform. The combination of stable isotope science with MRI represents a highly differentiated and innovative approach, with the potential to redefine how we image and monitor disease, particularly in areas such as brain cancer where current options are limited.
“In the near term, my focus will be on advancing the platform through clinical development, including first-in-human studies, while establishing a clear pathway toward regulatory approval and commercialisation.”
The framing of TrivarX as being at a “pivotal stage” acknowledges the company’s transition from technology development to clinical execution. Dr Meyrick’s emphasis on establishing a pathway toward regulatory approval and commercialisation signals an intent to advance beyond proof-of-concept studies toward market-focused development.
Non-Executive Chairman David Trimboli highlighted Dr Meyrick’s alignment with the company’s immediate requirements:
David Trimboli, Non-Executive Chairman
“Danielle’s appointment represents a significant step forward for TrivarX as the Company continues to transition toward clinical development and commercialisation of the Stabl-Im platform. Her deep expertise in radiopharmaceuticals, isotope science and clinical trial execution is highly aligned with our near-term requirements to advance this technology.”
The Chairman’s reference to “transition toward clinical development” positions the company at an inflection point between research-stage validation and clinical-stage execution. This framing provides context for investors assessing the company’s risk profile and development timeline.
The next major ASX story will hit our subscribers first
Near-term catalysts for investors to watch
Multiple de-risking milestones are scheduled within a 6-12 month window, providing defined events for investors to monitor progress against management’s stated objectives:
- Dr Meyrick commencement as CEO — 1 June 2026
- CRO selection and trial site activation — imminent
- Phase 1 safety study commencement — shortly
- Phase 1 completion (≥20 subjects) — targeted by end of calendar year 2026
- Pre-IND package preparation for FDA submission — within FY26/27
The clustering of these catalysts creates a concentrated period of operational activity that will determine whether TrivarX can execute its transition to clinical-stage company. Phase 1 completion by year-end provides a specific timeline for the first clinical data readout, a critical validation point for the Stabl-Im platform’s safety and preliminary efficacy in human subjects.
The pre-IND package submission milestone signals intent to engage with the FDA early in the development process, potentially positioning the company for regulatory feedback that could inform Phase 2 trial design and accelerate the pathway to market. For investors, these milestones establish accountability benchmarks against which management execution can be assessed over the coming quarters.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE ASX biotech alerts within minutes of release, complete with expert analysis. StockWire X delivers breaking news and in-depth coverage straight to your inbox. Click the “Free Alerts” button to stay ahead on clinical trial updates, regulatory milestones, and market-moving announcements.